C4 Therapeutics, Inc. (CCCC) — SEC Filings
C4 Therapeutics, Inc. (CCCC) — 50 SEC filings. Latest: ARS (Apr 29, 2026). Includes 20 8-K, 10 SC 13G/A, 7 SC 13G.
View C4 Therapeutics, Inc. on SEC EDGAR
Overview
C4 Therapeutics, Inc. (CCCC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 29, 2026: C4 Therapeutics, Inc. filed a DEFA14A on April 29, 2026, which contains additional definitive proxy soliciting materials. The filing includes graphic documents and a complete submission text file, detailing information relevant to shareholder decisions. The company's business address is 490 Arsenal
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for C4 Therapeutics, Inc. is neutral.
Filing Type Overview
C4 Therapeutics, Inc. (CCCC) has filed 1 ARS, 1 DEFA14A, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 7 SC 13G, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CCCC's 28 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $11.230M |
| Net Income | $-32.166M |
| EPS | $-0.44 |
| Debt-to-Equity | 0.72 |
| Cash Position | $58.809M |
| Operating Margin | -309.7% |
| Total Assets | $265.488M |
| Total Debt | N/A |
Key Executives
- Dr. Adam R. Schlegel
- Dr. Adam R. Schomer
- Dr. Steven M. Altschuler
- Dr. Andrew R. Allen
- Adam R. Schlegel
- Dr. Steven R. Deitcher
Industry Context
C4 Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and reliance on strategic partnerships for funding and market access. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Top Tags
biotech (8) · financials (5) · institutional-ownership (5) · 10-Q (4) · executive-appointment (4) · corporate-governance (3) · material-agreement (3) · Biotechnology (3) · 8-K (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $32.166M | Increased from $24.666M in Q3 2024, indicating widening losses. |
| Net Loss (YTD Sep 2025) | $84.508M | Increased from $70.743M in YTD Sep 2024, showing accelerating losses. |
| Collaboration Revenue (Q3 2025) | $11.230M | Decreased from $15.362M in Q3 2024, signaling a decline in partnership contributions. |
| Impairment of Long-Lived Assets | $10.733M | A new significant operating expense in 2025, impacting profitability and asset value. |
| Research and Development (Q3 2025) | $25.989M | Decreased from $31.838M in Q3 2024, potentially indicating a slowdown in R&D activities. |
| Current Marketable Securities (Sep 2025) | $133.075M | Significantly decreased from $189.405M at Dec 2024, reflecting cash utilization. |
| Total Assets (Sep 2025) | $265.488M | Decreased from $349.602M at Dec 2024, indicating a shrinking asset base. |
| Total Stockholders' Equity (Sep 2025) | $154.408M | Decreased from $215.986M at Dec 2024, reflecting accumulated losses. |
| SEC File Number | 001-39567 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 47-5617627 | Company's tax identification number. |
| Net Loss (Q2 2025) | $48.2M | Increased from $38.5M in Q2 2024, indicating widening losses. |
| Net Loss (YTD 2025) | $97.1M | Increased from $76.2M in YTD 2024, showing accelerated cash burn. |
| Increase in Q2 Net Loss | 25.2% | Calculated as ($48.2M - $38.5M) / $38.5M, highlighting accelerated losses. |
| Increase in YTD Net Loss | 27.4% | Calculated as ($97.1M - $76.2M) / $76.2M, indicating a significant rise in operational costs. |
| Common Stock Par Value | $0.0001 | Standard par value for common stock, indicating equity structure. |
Forward-Looking Statements
- {"claim":"Wasatch Advisors LP will maintain a significant stake in C4 Therapeutics, Inc. for the foreseeable future.","entity":"Wasatch Advisors LP","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for C4 Therapeutics, Inc. (CCCC)?
C4 Therapeutics, Inc. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 10 SC 13G/A, 7 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CCCC filings?
Across 50 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 42 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find C4 Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all C4 Therapeutics, Inc. (CCCC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for C4 Therapeutics, Inc.?
Key financial highlights from C4 Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CCCC?
The investment thesis for CCCC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at C4 Therapeutics, Inc.?
Key executives identified across C4 Therapeutics, Inc.'s filings include Dr. Adam R. Schlegel, Dr. Adam R. Schomer, Dr. Steven M. Altschuler, Dr. Andrew R. Allen, Adam R. Schlegel and 1 others.
What are the main risk factors for C4 Therapeutics, Inc. stock?
Of CCCC's 28 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from C4 Therapeutics, Inc.?
Recent forward-looking statements from C4 Therapeutics, Inc. include guidance on {"claim":"Wasatch Advisors LP will maintain a significant stake in C4 Therapeutics, Inc. for the foreseeable future.","e.